UNASSIGNED: Few @entity1 with relapsed/refractory @entity1892 ( @entity1892 ) achieve prolonged disease-free survival. Blinatumomab is a bispecific T-cell engaging (BiTE  ) antibody construct that transiently links CD3-positive T cells to @entity1075 -positive B cells. This phase 2 study evaluated stepwise (9-28-112   g/day with weekly dose increases; n=23) or flat (112   g/day; n=2) dosing of blinatumomab by continuous infusion, with @entity619 prophylaxis, in @entity1 with relapsed/refractory @entity1892 . @entity1 received a median of 3 prior lines of therapy. Median time since last regimen was 1.5 months. Seventeen @entity1 ended treatment in cycle 1 (induction), 7 in cycle 2 (consolidation), and 1 in retreatment. Among 21 evaluable @entity1 , the overall response rate (ORR) after 1 blinatumomab cycle was 43%, including complete response (CR) in 19%. Three @entity1 had late CR in follow-up without other treatment. The most common adverse events with stepwise dosing were @entity400 (48%), @entity221 (44%), @entity1295 (26%), and @entity4 (26%). Grade 3 neurologic events with stepwise dosing were @entity75 and @entity2026 (each 9%), and @entity400 , @entity8408 , @entity1296 , @entity2147 , and disorientation (each 4%). Of 5 (22%) @entity1 who discontinued stepwise dosing because of adverse events, 4 (17%) had neurologic events. Most neurologic events resolved. The flat dose cohort was stopped because of grade 3 neurologic events in both @entity1 . Blinatumomab monotherapy appears effective in @entity1 with relapsed/refractory @entity1892 , a heavily pretreated @entity1 population with a high unmet medical need. Further studies need to define the optimal approach to achieve the target dose without early dropout. The study was registered at www.clinicaltrials.gov as NCT01741792.

Phase 2 study of bispecific T-cell engager (BiTE  ) antibody blinatumomab in relapsed/refractory XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity1296 :: ('MESH:D004244', 'Disease') :: ['dizziness'] @entity1075 :: ('930', 'Gene') :: ['CD19'] @entity75 :: ('MESH:D001927', 'Disease') :: ['encephalopathy'] @entity4 :: ('MESH:D004487', 'Disease') :: ['edema'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity2147 :: ('MESH:D006970', 'Disease') :: ['somnolence'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['DLBCL', 'diffuse large B cell lymphoma'] @entity400 :: ('MESH:D014202', 'Disease') :: ['tremor'] @entity2026 :: ('MESH:D001037', 'Disease') :: ['aphasia'] @entity8408 :: ('MESH:D013064', 'Disease') :: ['speech disorder'] @entity221 :: ('MESH:D005334', 'Disease') :: ['pyrexia']
@entity1892 :: (MESH:D016393,Disease) :: ['diffuse large B cell lymphoma']
